IRON vs. PRAX, NRIX, LBPH, AUPH, PRTC, PAHC, NUVB, ARCT, CVAC, and SAGE
Should you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Praxis Precision Medicines (PRAX), Nurix Therapeutics (NRIX), Longboard Pharmaceuticals (LBPH), Aurinia Pharmaceuticals (AUPH), PureTech Health (PRTC), Phibro Animal Health (PAHC), Nuvation Bio (NUVB), Arcturus Therapeutics (ARCT), CureVac (CVAC), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical preparations" industry.
Praxis Precision Medicines (NASDAQ:PRAX) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership.
Praxis Precision Medicines and Disc Medicine both received 26 outperform votes by MarketBeat users. However, 74.29% of users gave Disc Medicine an outperform vote while only 63.41% of users gave Praxis Precision Medicines an outperform vote.
67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 4.2% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Disc Medicine has a net margin of 0.00% compared to Disc Medicine's net margin of -5,711.85%. Praxis Precision Medicines' return on equity of -22.81% beat Disc Medicine's return on equity.
Disc Medicine has lower revenue, but higher earnings than Praxis Precision Medicines. Disc Medicine is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
Praxis Precision Medicines currently has a consensus price target of $105.80, indicating a potential upside of 140.02%. Disc Medicine has a consensus price target of $57.71, indicating a potential upside of 68.36%. Given Disc Medicine's higher possible upside, research analysts clearly believe Praxis Precision Medicines is more favorable than Disc Medicine.
Praxis Precision Medicines has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.
In the previous week, Disc Medicine had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 6 mentions for Disc Medicine and 4 mentions for Praxis Precision Medicines. Disc Medicine's average media sentiment score of 1.09 beat Praxis Precision Medicines' score of 0.78 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Summary
Disc Medicine beats Praxis Precision Medicines on 11 of the 16 factors compared between the two stocks.
Get Disc Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Disc Medicine Competitors List
Related Companies and Tools
